Browse PTPRB

Summary
SymbolPTPRB
Nameprotein tyrosine phosphatase, receptor type, B
Aliases PTPB; HPTP-BETA; HPTPB; R-PTP-BETA; VEPTP; VE-PTP; protein tyrosine phosphatase, receptor type, beta polypep ......
Chromosomal Location12q15-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Single-pass type I membrane protein
Domain PF00041 Fibronectin type III domain
PF00102 Protein-tyrosine phosphatase
Function

Plays an important role in blood vessel remodeling and angiogenesis. Not necessary for the initial formation of blood vessels, but is essential for their maintenance and remodeling. Can induce dephosphorylation of TEK/TIE2, CDH5/VE-cadherin and KDR/VEGFR-2. Regulates angiopoietin-TIE2 signaling in endothelial cells. Acts as a negative regulator of TIE2, and controls TIE2 driven endothelial cell proliferation, which in turn affects blood vessel remodeling during embryonic development and determines blood vessel size during perinatal growth. Essential for the maintenance of endothelial cell contact integrity and for the adhesive function of VE-cadherin in endothelial cells and this requires the presence of plakoglobin (By similarity).

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0006470 protein dephosphorylation
GO:0016311 dephosphorylation
GO:0035335 peptidyl-tyrosine dephosphorylation
GO:0048514 blood vessel morphogenesis
Molecular Function GO:0004721 phosphoprotein phosphatase activity
GO:0004725 protein tyrosine phosphatase activity
GO:0005001 transmembrane receptor protein tyrosine phosphatase activity
GO:0016791 phosphatase activity
GO:0019198 transmembrane receptor protein phosphatase activity
GO:0042578 phosphoric ester hydrolase activity
Cellular Component GO:0043235 receptor complex
> KEGG and Reactome Pathway
 
KEGG hsa04520 Adherens junction
Reactome R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6798695: Neutrophil degranulation
Summary
SymbolPTPRB
Nameprotein tyrosine phosphatase, receptor type, B
Aliases PTPB; HPTP-BETA; HPTPB; R-PTP-BETA; VEPTP; VE-PTP; protein tyrosine phosphatase, receptor type, beta polypep ......
Chromosomal Location12q15-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PTPRB and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PTPRB and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
16489031GlioblastomaInhibit immunityTargeting of the receptor protein tyrosine phosphatase beta with a monoclonal antibody delays tumor growth in a glioblastoma model.
Summary
SymbolPTPRB
Nameprotein tyrosine phosphatase, receptor type, B
Aliases PTPB; HPTP-BETA; HPTPB; R-PTP-BETA; VEPTP; VE-PTP; protein tyrosine phosphatase, receptor type, beta polypep ......
Chromosomal Location12q15-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PTPRB in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPTPRB
Nameprotein tyrosine phosphatase, receptor type, B
Aliases PTPB; HPTP-BETA; HPTPB; R-PTP-BETA; VEPTP; VE-PTP; protein tyrosine phosphatase, receptor type, beta polypep ......
Chromosomal Location12q15-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PTPRB in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0940.761
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1020.885
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0850.873
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2090.55
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6610.761
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3530.89
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1940.629
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3890.772
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0180.99
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.0740.333
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.640.0574
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3650.00173
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PTPRB in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277322.21111.20.194
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275922.213.68.60.353
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211723.817.66.20.709
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8637.516.720.80.58
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.418.2-2.81
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382713.211.12.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221318.215.42.81
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.27.1-0.91
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPTPRB
Nameprotein tyrosine phosphatase, receptor type, B
Aliases PTPB; HPTP-BETA; HPTPB; R-PTP-BETA; VEPTP; VE-PTP; protein tyrosine phosphatase, receptor type, beta polypep ......
Chromosomal Location12q15-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PTPRB. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPTPRB
Nameprotein tyrosine phosphatase, receptor type, B
Aliases PTPB; HPTP-BETA; HPTPB; R-PTP-BETA; VEPTP; VE-PTP; protein tyrosine phosphatase, receptor type, beta polypep ......
Chromosomal Location12q15-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PTPRB. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PTPRB.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPTPRB
Nameprotein tyrosine phosphatase, receptor type, B
Aliases PTPB; HPTP-BETA; HPTPB; R-PTP-BETA; VEPTP; VE-PTP; protein tyrosine phosphatase, receptor type, beta polypep ......
Chromosomal Location12q15-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PTPRB. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPTPRB
Nameprotein tyrosine phosphatase, receptor type, B
Aliases PTPB; HPTP-BETA; HPTPB; R-PTP-BETA; VEPTP; VE-PTP; protein tyrosine phosphatase, receptor type, beta polypep ......
Chromosomal Location12q15-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PTPRB expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPTPRB
Nameprotein tyrosine phosphatase, receptor type, B
Aliases PTPB; HPTP-BETA; HPTPB; R-PTP-BETA; VEPTP; VE-PTP; protein tyrosine phosphatase, receptor type, beta polypep ......
Chromosomal Location12q15-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PTPRB and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPTPRB
Nameprotein tyrosine phosphatase, receptor type, B
Aliases PTPB; HPTP-BETA; HPTPB; R-PTP-BETA; VEPTP; VE-PTP; protein tyrosine phosphatase, receptor type, beta polypep ......
Chromosomal Location12q15-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PTPRB collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PTPRB.
ID Name Drug Type Targets #Targets
DB06989{4-[2-BENZYL-3-METHOXY-2-(METHOXYCARBONYL)-3-OXOPROPYL]PHENYL}SULFAMIC ACIDSmall MoleculePTPRB1
DB07068(4-{4-[(TERT-BUTOXYCARBONYL)AMINO]-2,2-BIS(ETHOXYCARBONYL)BUTYL}PHENYL)SULFAMIC ACIDSmall MoleculePTPRB1
DB07127{4-[2,2-BIS(5-METHYL-1,2,4-OXADIAZOL-3-YL)-3-PHENYLPROPYL]PHENYL}SULFAMIC ACIDSmall MoleculePTPRB1
DB08678(4-ETHYLPHENYL)SULFAMIC ACIDSmall MoleculePTPRB1